[Form 4] CYTOKINETICS INC Insider Trading Activity
Rhea-AI Filing Summary
Cytokinetics, Inc. reported an insider stock transaction by its President & CEO and Director on 12/03/2025. The filing shows the disposition of 5,930 shares of common stock at a price of $65.02 per share, recorded under transaction code F.
After this transaction, the reporting person directly beneficially owns 350,202 shares of Cytokinetics common stock. In addition, the filing notes indirect ownership of 2,083 shares held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held by The Brittany Blum 2003 Irrevocable Trust.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise Price or Tax Liability | Common Stock | 5,930 | $65.02 | $386K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (2)
- F1. Shares held by The Bridget Blum 2003 Irrevocable Trust.
- F2. Shares held by The Brittany Blum 2003 Irrevocable Trust.
FAQ
What insider transaction did Cytokinetics (CYTK) report in this Form 4?
The Form 4 reports that the President & CEO and Director of Cytokinetics, Inc. disposed of 5,930 shares of common stock on 12/03/2025 at a price of $65.02 per share, identified with transaction code F.
What is the role of the reporting person at Cytokinetics (CYTK)?
The reporting person is identified as both a Director and an Officer, serving as President & CEO of Cytokinetics, Inc.
Was this Cytokinetics (CYTK) Form 4 filed by more than one reporting person?
No. The Form 4 indicates that it was filed by one reporting person, not jointly with others.
Who signed the Cytokinetics (CYTK) Form 4?
The Form 4 was signed by /s/ John O. Faurescu as attorney-in-fact for Mr. Blum on 12/05/2025.
AI-generated analysis. How Rhea-AI works. Not financial advice.